Compare Rivian Automotive, Inc. (RIVN) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rivian Automotive, Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? Rivian Automotive, Inc. trades at $13.96 (market cap $20.75B), while State Street SPDR S&P Biotech ETF trades at $153.7 (market cap $10.11B). The key difference: Rivian Automotive, Inc. is far larger — about 2.1× State Street SPDR S&P Biotech ETF's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Rivian Automotive, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Rivian Automotive, Inc. for 61 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| RIVN | XBI | |
|---|---|---|
Market Cap | $20.75B | $10.11B |
Volume | 26,144,654 | 12,903,266 |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $22.45 | $169.55 |
52-Week Low | $12.50 | $104.99 |
Typical Hold Time | 61 Days | 38 Days |
Enterprise Value | $20.79B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Rivian Automotive (RIVN) trades at $13.96, down 2.65% amid bearish technical signals despite strong Q3 2026 delivery results. The company reported record production of 19,751 vehicles and deliveries of 19,248, beating estimates but maintaining unchanged guidance. Fundamentally, RIVN shows improving revenue growth ($5.39B in 2025) but continues significant losses (-$3.65B net income) with negative margins. Analyst consensus remains cautiously optimistic with a $16.89 price target, though technical indicators show 18 sell signals versus 2 buy signals.
Rivian's investment case balances strong delivery growth and R2 SUV ramp-up against persistent cash burn and competitive EV market pressures. The stock offers upside to analyst targets but faces execution risks in achieving profitability. Key catalysts include R2 production scaling and autonomy technology rollout, while main risks involve cash flow sustainability and intense industry competition.
XBI trades at $153.75, up 2.34% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts like the Merck-Moderna cancer vaccine breakthrough.
Outlook remains mixed with 100% analyst hold rating contrasting with bullish news catalysts. Key risks include high volatility, sector-specific regulatory pressures, and expense ratios higher than broader healthcare ETFs. The current technical setup near resistance requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Rivian Automotive, Inc.
Rivian Automotive, Inc. is an automotive technology company. The Company designs and manufactures vans, trucks, and sports utility vehicles, as well as offers repair and maintenance services. Rivian Automotive serves customers in North America and the United Kingdom.
Read more on RIVN →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
